135 related articles for article (PubMed ID: 38451491)
41. Long-term outcomes in patients with central and ultracentral non-small cell lung cancer treated with stereotactic body radiotherapy: single-institution experience.
Song X; Zhao L; Jiang N; Ding N; Zong D; Zhang N; Wang D; Wen J; He X; Kong C; Zhu X
Curr Probl Cancer; 2023 Jun; 47(3):100956. PubMed ID: 36966677
[TBL] [Abstract][Full Text] [Related]
42. Patient-reported quality of life after stereotactic ablative radiotherapy for early-stage lung cancer.
Lagerwaard FJ; Aaronson NK; Gundy CM; Haasbeek CJ; Slotman BJ; Senan S
J Thorac Oncol; 2012 Jul; 7(7):1148-54. PubMed ID: 22610256
[TBL] [Abstract][Full Text] [Related]
43. Phase II Trial of SBRT for Stage I NSCLC: Survival, Local Control, and Lung Function at 36 Months.
Navarro-Martin A; Aso S; Cacicedo J; Arnaiz M; Navarro V; Rosales S; de Blas R; Ramos R; Guedea F
J Thorac Oncol; 2016 Jul; 11(7):1101-11. PubMed ID: 27103512
[TBL] [Abstract][Full Text] [Related]
44. Long-term Overall Survival Outcomes in Patients with Early Stage, Peripherally Located, Non-small Cell Lung Cancer Treated with Stereotactic Ablative Radiotherapy in a Non-academic Cancer Centre.
Wood A; Aynsley E; Kumar G; Masinghe S; Anderson M; Veeratterapillay J; Huntley C; Blower A; Green J; Johnson D; Daniel J; Curtis H; Reynolds J; Turnbull M; Harland K; Swingler A; Banham E; Burke K; Bradley J; Greenhalgh A; Peedell C
Clin Oncol (R Coll Radiol); 2021 May; 33(5):283-291. PubMed ID: 33341333
[TBL] [Abstract][Full Text] [Related]
45. Stereotactic ablative radiotherapy of 60 Gy in eight fractions is safe for ultracentral non-small cell lung cancer.
Yang D; Cui J; Zhao J; You J; Yu R; Yu H; Jiang L; Li D; Xu B; Shi A
Thorac Cancer; 2020 Mar; 11(3):754-761. PubMed ID: 32012484
[TBL] [Abstract][Full Text] [Related]
46. Lobectomy, sublobar resection, and stereotactic ablative radiotherapy for early-stage non-small cell lung cancers in the elderly.
Shirvani SM; Jiang J; Chang JY; Welsh J; Likhacheva A; Buchholz TA; Swisher SG; Smith BD
JAMA Surg; 2014 Dec; 149(12):1244-53. PubMed ID: 25321323
[TBL] [Abstract][Full Text] [Related]
47. Outcomes of single fraction stereotactic ablative radiotherapy for lung metastases.
Filippi AR; Badellino S; Guarneri A; Levis M; Botticella A; Mantovani C; Ragona R; Racca P; Buffoni L; Novello S; Ricardi U
Technol Cancer Res Treat; 2014 Feb; 13(1):37-45. PubMed ID: 23819496
[TBL] [Abstract][Full Text] [Related]
48. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial.
Shaverdian N; Lisberg AE; Bornazyan K; Veruttipong D; Goldman JW; Formenti SC; Garon EB; Lee P
Lancet Oncol; 2017 Jul; 18(7):895-903. PubMed ID: 28551359
[TBL] [Abstract][Full Text] [Related]
49. Stereotactic Ablative Radiotherapy Using CyberKnife for Stage I Non-small-cell Lung Cancer: A Retrospective Analysis.
Hayashi K; Suzuki O; Shiomi H; Nakai M; Fujiwara K; Nakanishi E; Tatekawa S; Hirata T; Tamari K; Hirata H; Funaki S; Seo Y; Takeda Y; Isohashi F; Shintani Y; Ogawa K
Anticancer Res; 2022 Jan; 42(1):321-327. PubMed ID: 34969740
[TBL] [Abstract][Full Text] [Related]
50. Feasible Optimization of Stereotactic Ablative Radiotherapy Dose by Tumor Size for Stage I Non-small-cell Lung Cancer.
Lee S; Song SY; Kim SS; Choi W; Je HU; Back GM; Cho B; Jeong SY; Choi EK
Clin Lung Cancer; 2018 Mar; 19(2):e253-e261. PubMed ID: 29196082
[TBL] [Abstract][Full Text] [Related]
51. Long-term clinical experience of high-dose ablative lung radiotherapy: high pre-treatment [18F]fluorodeoxyglucose-positron emission tomography maximal standardized uptake value of the primary tumor adversely affects treatment outcome.
Lee DS; Kim YS; Yoo IeR; Kang YN; Kim SJ; Oh JK; Kim YK; Wang YP; Park JG; Kang JH; Han DH; Ahn MI; Lee KY
Lung Cancer; 2013 May; 80(2):172-8. PubMed ID: 23489556
[TBL] [Abstract][Full Text] [Related]
52. Single-Fraction vs Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases (SAFRON II): The Trans Tasman Radiation Oncology Group 13.01 Phase 2 Randomized Clinical Trial.
Siva S; Bressel M; Mai T; Le H; Vinod S; de Silva H; Macdonald S; Skala M; Hardcastle N; Rezo A; Pryor D; Gill S; Higgs B; Wagenfuehr K; Montgomery R; Awad R; Chesson B; Eade T; Wong W; Sasso G; De Abreu Lourenco R; Kron T; Ball D; Neeson P;
JAMA Oncol; 2021 Oct; 7(10):1476-1485. PubMed ID: 34455431
[TBL] [Abstract][Full Text] [Related]
53. Stereotactic Body Radiotherapy Reirradiation Is Safe in Patients With Lung Cancer With In-Field Enlarged Tumor Recurrence.
Berber T; Yıldırım BA; Kandemir Gürsel Ö
Technol Cancer Res Treat; 2024; 23():15330338231208616. PubMed ID: 38860536
[No Abstract] [Full Text] [Related]
54. A comparison between accelerated hypofractionation and stereotactic ablative radiotherapy (SABR) for early-stage non-small cell lung cancer (NSCLC): Results of a propensity score-matched analysis.
Chiang A; Thibault I; Warner A; Rodrigues G; Palma D; Soliman H; Jain S; Poon I; Cheung P
Radiother Oncol; 2016 Mar; 118(3):478-84. PubMed ID: 26795773
[TBL] [Abstract][Full Text] [Related]
55. Stereotactic ablative radiotherapy: a potentially curable approach to early stage multiple primary lung cancer.
Chang JY; Liu YH; Zhu Z; Welsh JW; Gomez DR; Komaki R; Roth JA; Swisher SG
Cancer; 2013 Sep; 119(18):3402-10. PubMed ID: 23798353
[TBL] [Abstract][Full Text] [Related]
56. Stereotactic ablative radiotherapy (SABR) using 70 Gy in 10 fractions for non-small cell lung cancer: exploration of clinical indications.
Li Q; Swanick CW; Allen PK; Gomez DR; Welsh JW; Liao Z; Balter PA; Chang JY
Radiother Oncol; 2014 Aug; 112(2):256-61. PubMed ID: 25108807
[TBL] [Abstract][Full Text] [Related]
57. Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial.
Phillips R; Shi WY; Deek M; Radwan N; Lim SJ; Antonarakis ES; Rowe SP; Ross AE; Gorin MA; Deville C; Greco SC; Wang H; Denmeade SR; Paller CJ; Dipasquale S; DeWeese TL; Song DY; Wang H; Carducci MA; Pienta KJ; Pomper MG; Dicker AP; Eisenberger MA; Alizadeh AA; Diehn M; Tran PT
JAMA Oncol; 2020 May; 6(5):650-659. PubMed ID: 32215577
[TBL] [Abstract][Full Text] [Related]
58. Clinical outcome and predictors of survival and pneumonitis after stereotactic ablative radiotherapy for stage I non-small cell lung cancer.
Chang JY; Liu H; Balter P; Komaki R; Liao Z; Welsh J; Mehran RJ; Roth JA; Swisher SG
Radiat Oncol; 2012 Sep; 7():152. PubMed ID: 22963661
[TBL] [Abstract][Full Text] [Related]
59. Assessment of a Contralateral Esophagus-Sparing Technique in Locally Advanced Lung Cancer Treated With High-Dose Chemoradiation: A Phase 1 Nonrandomized Clinical Trial.
Kamran SC; Yeap BY; Ulysse CA; Cronin C; Bowes CL; Durgin B; Gainor JF; Khandekar MJ; Tansky JY; Keane FK; Olsen CC; Willers H
JAMA Oncol; 2021 Jun; 7(6):910-914. PubMed ID: 33830168
[TBL] [Abstract][Full Text] [Related]
60. Long term efficacy and toxicity after stereotactic ablative reirradiation in locally relapsed stage III non-small cell lung cancer.
Sumodhee S; Bondiau PY; Poudenx M; Cohen C; Naghavi AO; Padovani B; Maneval D; Gal J; Leysalle A; Ghalloussi H; Otto J; Doyen J
BMC Cancer; 2019 Apr; 19(1):305. PubMed ID: 30943943
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
